Gene
TERT
TERT is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (110), Actionable biomarkers (1), Trial mentions (108), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention TERT. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 2 with a planned future start.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 14 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 9 of 8,738 | 0.10% | not measured | |
| 2025 | 12 of 8,875 | 0.14% | not measured | |
| 2024 | 10 of 8,597 | 0.12% | not measured | |
| 2023 | 6 of 8,275 | 0.07% | 48 of 11,460 | 0.42% |
| 2022 | 13 of 8,285 | 0.16% | 48 of 13,598 | 0.35% |
| 2021 | 4 of 8,692 | 0.05% | 60 of 15,045 | 0.40% |
| 2020 | 7 of 7,640 | 0.09% | 45 of 14,459 | 0.31% |
| 2019 | 3 of 7,300 | 0.04% | 44 of 12,159 | 0.36% |
| 2018 | 11 of 6,927 | 0.16% | 49 of 11,854 | 0.41% |
| 2017 | 4 of 6,558 | 0.06% | 33 of 11,595 | 0.28% |
Showing 10 of 37 years.
Assay-provider ledger (110)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| U-Monitor, Porto, Portugal | Diagnostic provider | Clinical validation | 2 | July 01, 2026 |
| STRATIFYER Molecular Pathology GmbH | Diagnostic provider | Clinical validation | 2 | June 01, 2026 |
| U Monitor Lda | Diagnostic provider | Clinical validation | 2 | June 01, 2026 |
| University of Pittsburgh Medical Center | Not a company | Clinical validationAnalytical validation | 3 | April 01, 2026 |
| Dxome Co. Ltd. | Diagnostic provider | Clinical validationAnalytical validation | 1 | March 01, 2026 |
Showing 5 of 110 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| TERT promoters core | ERIBULIN MESYLATE | response-associated | glioblastoma multiforme | Cancer Genome Interpreter |
Trial mentions (108)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT04586946 | Trial biospecimen (AACT) |
| NCT05544149 | Trial eligibility (AACT) |
| NCT00733343 | Trial eligibility (AACT) |
| NCT03382977 | Trial eligibility (AACT) |
| NCT01659606 | Trial eligibility (AACT) |
Showing 5 of 108 trial mentions.
Target-disease associations (707)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Abdominal Aortic Aneurysm | cardiovascular disease | GWAS credible sets |
| Abnormal pulmonary interstitial morphology | phenotype | Variant curation (ClinVar / EVA) |
| Abnormal pulmonary interstitial morphology | phenotype | gene burden |
| Abnormality of blood and blood-forming tissues | phenotype | GWAS credible sets |
| Allergy | phenotype | Literature (Europe PMC) |
Showing 5 of 707 associations.
Vendor sourcing (474)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.000004). A missense variant is a common mechani... | View ClinVar record SCV002318673.1 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The TERT c.3329C>T; p.Thr1110Met variant (rs199422306, ClinVar Variation ID: 39122) is reported in the literature in individuals affected with idiopathic pul... | View ClinVar record SCV005877736.1 |
| Aalborg University Hospital | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Histologically or cytologically confirmed small-cell lung cancer * Previous radiotherapy to the thorax is allowed as long as the patient can receive TRT... | View trial NCT03540420 |
| Aalborg University Hospital | Trial collaborator | Mentioned in trial textTrial free-text mention | TRT | View trial NCT03540420 |
| Acerus Pharmaceuticals Corporation (Canada) | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Voluntarily sign and date the study consent form(s), which have been approved by an Institutional Review Board (IRB). Written consent must be obtained ... | View trial NCT04439799 |
Showing 5 of 474 sourcing records.
Trial-cited literature (539)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Circulating Tumor DNA and Response to Cisplatin-based Chemotherapy in Patients with Metastatic Urothelial Carcinoma Enrolled in CALGB 90601 (Alliance). | European urology open science | 2025 | 4 |
| Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation histological grade 2/3 gliomas: An extension retrospective analysis of a randomized controlled trial. | Cancer | 2025 | 2 |
| Rapid diagnosis of adult-type diffuse glioma using a layered scheme. | BMC medicine | 2025 | 2 |
| Preoperative plasma cell-free DNA chromosomal instability predicts microvascular invasion in hepatocellular carcinoma: a prospective study. | BMC cancer | 2025 | 2 |
| Alcohol-associated liver disease. | The Journal of clinical investigation | 2024 | 277 |
Showing 5 of 539 papers.
Protein variant mentions (97)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A184T | 1 | 2015 | PMID 25741868 |
| p.A202T | 5 | 2005 to 2015 | PMID 25741868, PMID 22424236, PMID 20858879 |
| p.A210T | 1 | 2015 | PMID 25741868 |
| p.A542S | 1 | 2015 | PMID 25741868 |
| p.A615T | 1 | 2015 | PMID 25741868 |
Showing 5 of 97 variants.
Literature-extracted relations (121)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Hydrogen Peroxide | Chemical | associate |
Oxidative stress and the subcellular localization of the telomerase reverse transcriptase (TERT) in papillary thyroid cancer. | 2016 |
| Estradiol | Chemical | negative_correlate |
Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. | 2009 |
| Glioma | Disease | associate |
Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation histological grade 2/3 gliomas: An extension retrospective analysis of a randomized controlled trial. | 2025 |
| Lymphoma, Follicular | Disease | associate |
Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation histological grade 2/3 gliomas: An extension retrospective analysis of a randomized controlled trial. | 2025 |
| Glioma | Disease | associate |
Rapid diagnosis of adult-type diffuse glioma using a layered scheme. | 2025 |
Showing 5 of 121 relation assertions.
Organizations publishing (590)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 44 | 2000 to 2024 |
| Memorial Sloan Kettering Cancer Center | Hospital | 30 | 2014 to 2025 |
| Mass General Brigham | Hospital | 20 | 2009 to 2023 |
| Dana-Farber Cancer Institute | Other | 16 | 2015 to 2025 |
| Harvard Medical School | Academic | 16 | 2012 to 2024 |
Showing 5 of 590 organizations.
Where TERT appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- integumentary system disease
- measurement
- medical procedure
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
560 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.